Jeffrey W. Johannes, Ph.D.
Affiliations: | 2005 | Harvard University, Cambridge, MA, United States |
Area:
synthesis of natural productsGoogle:
"Jeffrey Johannes"Mean distance: 7.87 | S | N | B | C | P |
Parents
Sign in to add mentor| Yoshito Kishi | grad student | 2005 | Harvard | |
| (Gymnodimine synthetic studies featuring a biomimetic, macrocycle forming Diels -Alder reaction.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Escobar RA, Johannes JW. (2020) A Unified and Practical Method for Carbon-Heteroatom Cross-Coupling using Nickel/Photo Dual Catalysis. Chemistry (Weinheim An Der Bergstrasse, Germany) |
| Howard RT, Hemsley P, Petteruti P, et al. (2020) Structure-guided design and in-cell target profiling of a cell-active target engagement probe for PARP inhibitors. Acs Chemical Biology |
| Tron AE, Belmonte MA, Adam A, et al. (2018) Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nature Communications. 9: 5341 |
| Wang Z, Grosskurth SE, Cheung T, et al. (2018) Pharmacological inhibition of PARP6 triggers multipolar spindle formation and elicits therapeutic effects in breast cancer. Cancer Research |
| Gingipalli L, Block MH, Bao L, et al. (2018) Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinases. Bioorganic & Medicinal Chemistry Letters |
| Leo E, Johannes J, Illuzzi G, et al. (2018) Abstract LB-273: A head-to-head comparison of the properties of five clinical PARP inhibitors identifies new insights that can explain both the observed clinical efficacy and safety profiles Cancer Research. 78 |
| Konev MO, McTeague TA, Johannes JW. (2018) Nickel-Catalyzed Photoredox-Mediated Cross-Coupling of Aryl Electrophiles and Aryl Azides Acs Catalysis. 8: 9120-9124 |
| Johannes J, Denz CR, Su N, et al. (2017) Structure Based Design of Selective Non-covalent CDK12 Inhibitors. Chemmedchem |
| Johannes JW, Bates S, Beigie C, et al. (2017) Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors. Acs Medicinal Chemistry Letters. 8: 239-244 |
| Hird AW, Secrist JP, Adam A, et al. (2017) Abstract DDT01-02: AZD5991: A potent and selective macrocyclic inhibitor of Mcl-1 for treatment of hematologic cancers Cancer Research. 77 |